Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and 13,14-dihydroprostaglandin e1

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with 13,14-dihydroprostaglandin e1 in 1 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Studies
(13,14-dihydroprostaglandin e1)		Trials
(13,14-dihydroprostaglandin e1)		Recent Studies (post-2010) (13,14-dihydroprostaglandin e1)
9,1561875522723

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Braun, M; Bruch, L; Ney, P; Schrör, K; Szymanski, C1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and 13,14-dihydroprostaglandin e1

ArticleYear
Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)--an in vivo metabolite of PGE1 in man.
    Eicosanoids, 1991, Volume: 4, Issue:3

    Topics: Alprostadil; Animals; Blood Platelets; Glucuronidase; Humans; In Vitro Techniques; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Platelet Activating Factor; Rabbits; Superoxides; Vasodilation

1991